Trials / Completed
CompletedNCT04574284
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer
A Open-label, Multicenter Phase II Study of TQB2450 Injection or Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 170 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to evaluate the efficacy and safety of TQB2450 injection or combined with anlotinib hydrochloride capsule in the treatment of recurrent or metastatic advanced endometrial cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB2450 | TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors. |
| DRUG | Anlotinib | A multi-target receptor tyrosine kinase inhibitor. |
Timeline
- Start date
- 2020-09-29
- Primary completion
- 2023-11-09
- Completion
- 2024-05-09
- First posted
- 2020-10-05
- Last updated
- 2025-05-28
Locations
36 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04574284. Inclusion in this directory is not an endorsement.